| 引用本文: | 白晓慧,陈荣荣,包哈申.蒙药珍宝丸在缺血性脑卒中全周期防治中的研究进展[J].中国现代应用药学,2026,43(18):120-130. |
| baixiaohui,chenrongrong,baohashen.Research Progress on Zhenbao Pill (Erdun-Wurile) in the Full-Cycle Prevention and Management of Ischemic Stroke[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(18):120-130. |
|
| 摘要: |
| 缺血性脑卒中(ischemic stroke,IS)是导致死亡和长期残疾的重要脑血管病,其急性期治疗受时间窗、出血风险等因素限制,神经修复、功能恢复及复发预防仍需长期管理。蒙药珍宝丸(额尔敦-乌日勒,Erdun-Wurile,EW)具有多成分、多靶点和多通路作用特点。本文基于动物、细胞及临床研究,综述EW在IS全周期防治中的研究进展。现有证据显示,EW在预防阶段主要涉及调节血脂、减轻血管炎症及稳定动脉粥样硬化斑块;急性期可通过调控氧化应激、铁死亡、细胞凋亡及神经炎症减轻缺血再灌注损伤;恢复期可能参与神经营养、免疫调节和血管新生;后遗症期部分临床研究提示其对神经功能、日常生活能力及认知结局具有辅助改善作用。总体而言,EW具有一定实验和临床研究基础,但现有临床证据多来自小样本、单中心或联合治疗研究,其独立疗效、复发预防作用及长期安全性仍需高质量临床研究进一步验证。此外,现有安全性和质量控制证据有限,尚缺乏系统的长期毒性监测及批间一致性质控体系,后续需建立多批次指纹图谱等标准化评价方法。 |
| 关键词: 缺血性脑卒中 全周期防治 蒙药珍宝丸 作用机制 临床证据 |
| DOI: |
| 分类号: |
| 基金项目:蒙医心脑互联理论体系构建及传统疗法现代研究 |
|
| Research Progress on Zhenbao Pill (Erdun-Wurile) in the Full-Cycle Prevention and Management of Ischemic Stroke |
|
baixiaohui,chenrongrong,baohashen
|
|
Inner Mongolia Medical University
|
| Abstract: |
| Ischemic stroke (IS) is a major cerebrovascular disease associated with high mortality and long-term disability. Although reperfusion therapies can improve outcomes in selected patients, their clinical application remains limited by therapeutic time windows and the risk of hemorrhagic complications, while neurological repair, functional recovery, and recurrence prevention require long-term management. Zhenbao Pill (Erdun-Wurile, EW), a traditional Mongolian medicine formula, is characterized by multi-component, multi-target, and multi-pathway pharmacological effects. This review summarizes current animal, cellular, and clinical evidence regarding the potential role of EW throughout the full-cycle management of IS. Existing studies suggest that, during the preventive stage, EW may regulate lipid metabolism, attenuate vascular inflammation, and improve atherosclerotic plaque stability. In the acute stage, it may alleviate ischemia–reperfusion injury by modulating oxidative stress, ferroptosis, apoptosis, and neuroinflammation. During the recovery stage, EW may contribute to neurotrophic support, immune regulation, and angiogenesis. In the sequelae stage, limited clinical studies suggest potential adjunctive benefits for neurological function, activities of daily living, and cognitive outcomes. Overall, EW has accumulated a certain body of experimental and clinical evidence; however, current clinical studies are predominantly small-sample, single-center, or combination-treatment studies. Its independent therapeutic efficacy, role in recurrence prevention, and long-term safety therefore require further confirmation in high-quality clinical trials. In addition, safety and quality-control evidence remains limited, with a lack of systematic long-term toxicity monitoring and batch-to-batch consistency control; standardized approaches such as multi-batch chemical fingerprinting are still needed. |
| Key words: ischemic stroke full-cycle prevention and management Zhenbao Pill mechanism clinical evidence |